Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F11 | P03951 | 15/20 | 0.43 |
| ▸ | KLK1 | P06870 | 5/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 5/20 | 0.37 |
| ▸ | F2 | P00734 | 1/20 | 0.33 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30258811 | 0.93 | F11 (0.47) | F11KLK1NOTUMF2KLKB1 | |
| SCHEMBL30258533 | 0.76 | F11 (0.44) | F11KLK1NOTUMF2KLKB1 | |
| SCHEMBL30258496 | 0.74 | F11 (0.54) | F11KLK1NOTUMF2KLKB1 | |
| SCHEMBL31186980 | 0.74 | F11 (0.46) | F11KLK1F2KLKB1 | |
| SCHEMBL31174073 | 0.71 | F11 (0.40) | F11KLK1NOTUM | |
| SCHEMBL29227930 | 0.70 | F11 (0.39) | F11KLK1NOTUMKLKB1 | |
| SCHEMBL30994997 | 0.70 | F11 (0.39) | F11KLK1NOTUMKLKB1 | |
| SCHEMBL31174085 | 0.70 | F11 (0.41) | F11KLK1NOTUM | |
| SCHEMBL31174097 | 0.69 | F11 (0.38) | F11KLK1NOTUMKLKB1 | |
| SCHEMBL31174077 | 0.69 | F11 (0.39) | F11KLK1NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11814364-B2 | Pyridine N-oxide derivatives useful as factor XIa inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-14 | — | — | US | disclosed |
| US-20230091768-A1 | PYRIDINE N-OXIDE DERIVATIVES USEFUL AS FACTOR XIA INHIBITORS | JANSSEN RESEARCH & DEVELOPMENT, LLC | 2023-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230091768-A1 | PYRIDINE N-OXIDE DERIVATIVES USEFUL AS FACTOR XIA INHIBITORS | F11, F2, KLKB1 | F11 1/4885KLK1 20/4885NOTUM 2057/4885 |
| US-11814364-B2 | Pyridine N-oxide derivatives useful as factor XIa inhibitors | F11, F2, KLKB1 | F11 1/4885KLK1 20/4885NOTUM 2057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.